These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29603899)

  • 1. The adoption of generic immunosuppressant medications in kidney, liver, and heart transplantation among recipients in Colorado or nationally with Medicare part D.
    Liu Q; Smith AR; Park JM; Oguntimein M; Dutcher S; Bello G; Helmuth M; Turenne M; Balkrishnan R; Fava M; Beil CA; Saulles A; Goel S; Sharma P; Leichtman A; Zee J
    Am J Transplant; 2018 Jul; 18(7):1764-1773. PubMed ID: 29603899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients.
    Kim JM; Kwon CHD; Joh JW; Sinn DH; Choi GS; Park JB; Kang ES; Lee SK
    Med Princ Pract; 2017; 26(3):221-228. PubMed ID: 28092916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients.
    Heavner MS; Tichy EM; Yazdi M; Formica RN; Kulkarni S; Emre S
    Am J Health Syst Pharm; 2013 Sep; 70(17):1507-12. PubMed ID: 23943182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients.
    Duong SQ; Lal AK; Joshi R; Feingold B; Venkataramanan R
    Pediatr Transplant; 2015 Dec; 19(8):911-7. PubMed ID: 26497983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function.
    Momper JD; Ridenour TA; Schonder KS; Shapiro R; Humar A; Venkataramanan R
    Am J Transplant; 2011 Sep; 11(9):1861-7. PubMed ID: 21714845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic maintenance immunosuppression in solid organ transplant recipients.
    Ensor CR; Trofe-Clark J; Gabardi S; McDevitt-Potter LM; Shullo MA
    Pharmacotherapy; 2011 Nov; 31(11):1111-29. PubMed ID: 22026398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.
    Tsipotis E; Gupta NR; Raman G; Zintzaras E; Jaber BL
    Am J Nephrol; 2016; 44(3):206-18. PubMed ID: 27576318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic Tacrolimus (Tacrobell
    Kim JM; Joh JW; Choi GS; Lee SK
    Drug Des Devel Ther; 2019; 13():4431-4438. PubMed ID: 32021085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values.
    Leino AD; King EC; Jiang W; Vinks AA; Klawitter J; Christians U; Woodle ES; Alloway RR; Rohan JM
    Am J Transplant; 2019 May; 19(5):1410-1420. PubMed ID: 30506623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.
    Ross JS; Rohde S; Sangaralingham L; Brito JP; Choi L; Dutcher SK; Graham DJ; Jenkins MR; Lipska KJ; Mendoza M; Qiang Y; Wang Z; Wu Y; Yao X; Shah ND
    J Clin Endocrinol Metab; 2019 Jun; 104(6):2305-2314. PubMed ID: 30690529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter experience with generic tacrolimus conversion.
    McDevitt-Potter LM; Sadaka B; Tichy EM; Rogers CC; Gabardi S
    Transplantation; 2011 Sep; 92(6):653-7. PubMed ID: 21788920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter case series documenting Medicare Part D plan denials of immunosuppressant drug coverage for organ transplant recipients.
    Lushin EN; McDermott JK; Truax C; Lourenco LM; Mariski M; Melaragno JI; Potter LM
    Am J Transplant; 2021 Feb; 21(2):889-896. PubMed ID: 32976706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic tacrolimus in solid organ transplantation.
    Taube D; Jones G; O'Beirne J; Wennberg L; Connor A; Rasmussen A; Backman L
    Clin Transplant; 2014 May; 28(5):623-32. PubMed ID: 24750309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in brand and generic drug utilization for dermatology providers from 2013-2019.
    Mazmudar RS; Tripathi R; Bordeaux JS; Scott JF
    Arch Dermatol Res; 2023 May; 315(4):1041-1044. PubMed ID: 36309878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the US Medicare Part D coverage gaps on medication use among patients with depression and heart failure.
    Baik SH; Rollman BL; Reynolds CF; Lave JR; Smith KJ; Zhang Y
    J Ment Health Policy Econ; 2012 Sep; 15(3):105-18. PubMed ID: 23001279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.